Biotech News
Related news
INVAInnoviva2026-06-16 12:00 EST
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
INVAInnoviva2026-10-19 12:00 EST
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
FULCFulcrum Therapeutics2026-08-17 11:00 EST
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
FULCFulcrum Therapeutics2026-06-01 20:05 EST
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
BCRXBioCryst Pharmaceuticals2026-10-29 11:00 EST
BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
ENTAEnanta Pharmaceuticals2026-10-26 11:00 EST
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
RHHBYRoche Holdings AG2026-10-16 05:00 EST
FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
ENTAEnanta Pharmaceuticals2026-10-13 11:00 EST
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
RHHBYRoche Holdings AG2026-11-16 06:00 EST
Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy
JNJJohnson & Johnson2026-10-19 12:23 EST
Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula
Innoviva
Diversified Biopharmaceutical Model Innoviva combines a respiratory-royalty portfolio, a commercial critical-care and infectious-disease business, and strategic investments in healthcare companies. Respiratory Royalties The company receives royalties from respiratory medicines partnered with GSK, providing cash flows that support...
Recent company news
INVAInnoviva2026-11-04 21:05 EST
Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress
INVAInnoviva2026-10-19 12:00 EST
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
INVAInnoviva2026-09-02 12:00 EST
Innoviva to Participate in Upcoming Investor Conferences
INVAInnoviva2026-08-11 20:05 EST
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
INVAInnoviva2026-08-05 20:05 EST
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Stock data
- Close
- 18.41 USD
- Market cap
- 1.58B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
